<div id="readability-page-1"><p>Shares of Boston Scientific (BSX) are down 17% after the medical-device maker issued forward guidance that disappointed Wall Street.</p><h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>The company issued fourth-quarter 2025 financial results that beat Wall Street estimates. Boston Scientific, which makes pacemakers and stents used to treat heart conditions, reported earnings per share (EPS) of $0.80, above analysts' consensus forecast of $0.78. </p> <p>Revenue in the final months of last year totaled $5.29 billion, up 12.7% from a year earlier and ahead of the $5.28 billion forecast on Wall Street. Despite the decent print, BSX stock is plunging after the company delivered an outlook that fell short of expectations. </p> <h2><strong>Boston Scientific's Disappointing Guidance</strong></h2> <p>Looking ahead, Boston Scientific said that it expects 8.5% to 10% revenue growth and earnings of $0.78 to $0.80 for the current first quarter. Analysts had been looking for 9.8% sales growth and a profit of $0.80 a share from the company. </p> <p>For all of 2026, Boston Scientific forecast per-share earnings of $3.43 to $3.49 and revenue growth of 10% to 11%. The full-year outlook is in line with analysts' consensus estimates. Boston Scientific recently announced that it is acquiring Penumbra (PEN), a maker of cardiovascular devices, for $14.5 billion.</p> <h2><strong>Is BSX Stock a Buy?</strong></h2></div>

SBIO

<p>Boston Scientific (BSX) shares fell 17% following disappointing forward guidance despite reporting strong fourth-quarter 2025 results, with EPS of $0.80 and revenue of $5.29 billion. The company anticipates 8.5% to 10% revenue growth and earnings of $0.78 to $0.80 for Q1, below analyst expectations. For 2026, BSX forecasts earnings of $3.43 to $3.49 per share and revenue growth of 10% to 11%, aligning with consensus estimates. Additionally, BSX is acquiring Penumbra for $14.5 billion.</p>

BSX Earnings: Boston Scientific Stock (BSX) Plunges 17% on Weak Guidance